IP Library › Granted Patent US 12,209,120
Granted Patent B2
US 12,209,120 · App. 17/245,713 · Granted Jan 28, 2025

Activatable anti-VEGF scFv

Inventors: Patrick Sean Daugherty (Santa Barbara, CA); Nancy Stagliano (Santa Barbara, CA); Jerry Thomas (Goleta, CA); Kathryn Kamath (Santa Barbara, CA); James W. West (Santa Barbara, CA); Sanjay Khare (Newbury Park, CA); Jason Sagert (Santa Barbara, CA)
Assignees: The Regents of the University of California; CytomX Therapeutics, Inc.
C07K16/22C07K16/24C07K16/2818C07K16/2836C07K16/42C12N15/1034C12N15/1044C07K2317/34C07K2317/622C07K2319/00C07K2319/30C07K2319/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,120
App. No.
17/245,713
Granted
Jan 28, 2025
Kind
B2
Abstract

The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.

Claims (3)

1. An activatable binding polypeptide (ABP), comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 54, 56, 58, 60, and 62.

2. An isolated nucleic acid molecule encoding the ABP of claim 1 .

3. A method of producing the ABP of claim 1 by culturing a cell under conditions that lead to expression of the ABP, wherein the cell comprises a vector comprising the isolated nucleic acid molecule of claim 2 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2021
From: STAGLIANO, NANCY E.; KAMATH, KATHRYN; KHARE, SANJAY; WEST, JAMES W.
To: CYTOMX, LLC
Reel/Frame 056148/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2021
From: CYTOMX THERAPEUTICS, LLC
To: CYTOMX THERAPEUTICS, INC.
Reel/Frame 056148/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2021
From: DAUGHERTY, PATRICK; THOMAS, JERRY
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 056148/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2021
From: SAGERT, JASON
To: CYTOMX THERAPEUTICS, INC.
Reel/Frame 056149/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2021
From: CYTOMX, LLC
To: CYTOMX THERAPEUTICS, LLC
Reel/Frame 056151/0924 →
Continuity (9)
Continuation 16102531 · Aug 13, 2018
Continuation 14853840 · Sep 14, 2015
Continuation 13950174 · Jul 24, 2013
Continuation 13413447 · Mar 6, 2012
Continuation 12196269 · Aug 21, 2008
Provisional Application 61052986 · May 13, 2008
Provisional Application 60957453 · Aug 22, 2007
Provisional Application 60957449 · Aug 22, 2007
Related Publication 20220098294A1 · Mar 31, 2022
References Cited (339)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 4379145A · Masuho et al. · 1983 [cited by applicant]
US 4671958A · Rodwell et al. · 1987 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4867973A · Goers et al. · 1989 [cited by applicant]
US 4952394A · Senter · 1990 [cited by applicant]
US 4975278A · Senter et al. · 1990 [cited by applicant]
US 5010176A · Barton · 1991 [cited by applicant]
US 5144012A · Johnson et al. · 1992 [cited by applicant]
US 5162218A · Schultz · 1992 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5272253A · Koppel et al. · 1993 [cited by applicant]
US 5306731A · Epstein · 1994 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5468785A · Greuel et al. · 1995 [cited by applicant]
US 5525491A · Huston et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5637288A · Goldenburg et al. · 1997 [cited by applicant]
US 5665358A · Barton et al. · 1997 [cited by applicant]
US 5679548A · Barbas et al. · 1997 [cited by applicant]
US 5725856A · Hudziak et al. · 1998 [cited by applicant]
US 5770195A · Hudziak et al. · 1998 [cited by applicant]
US 5772997A · Hudziak et al. · 1998 [cited by applicant]
US 5834247A · Comb et al. · 1998 [cited by applicant]
US 5837500A · Ladner et al. · 1998 [cited by applicant]
US 5866341A · Spinella et al. · 1999 [cited by applicant]
US 5922845A · Deo et al. · 1999 [cited by applicant]
US 5985626A · Barbas et al. · 1999 [cited by applicant]
US 5990286A · Khawli et al. · 1999 [cited by applicant]
US 5994104A · Anderson et al. · 1999 [cited by applicant]
US 6015557A · Tobinick et al. · 2000 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6066719A · Zapata · 2000 [cited by applicant]
US 6107059A · Hart et al. · 2000 [cited by applicant]
US 6165464A · Hudziak et al. · 2000 [cited by applicant]
US 6217866B1 · Schlessinger et al. · 2001 [cited by applicant]
US 6235883B1 · Jakobovitis et al. · 2001 [cited by applicant]
US 6258562B1 · Salfeld et al. · 2001 [cited by applicant]
US 6265540B1 · Isaacs et al. · 2001 [cited by applicant]
US 6268488B1 · Barbas et al. · 2001 [cited by applicant]
US 6342219B1 · Thorpe et al. · 2002 [cited by applicant]
US 6342221B1 · Thorpe et al. · 2002 [cited by applicant]
US 6399063B1 · Hudziak et al. · 2002 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 6534061B1 · Goddard et al. · 2003 [cited by applicant]
US 6682736B1 · Hansen et al. · 2004 [cited by applicant]
US 6884879B1 · Baca et al. · 2005 [cited by applicant]
US 6955900B1 · Barbas et al. · 2005 [cited by applicant]
US 6979538B2 · Ladner et al. · 2005 [cited by applicant]
US 6984720B1 · Korman et al. · 2006 [cited by applicant]
US 6992174B2 · Gillies et al. · 2006 [cited by applicant]
US 7029874B2 · Baker et al. · 2006 [cited by applicant]
US 7060269B1 · Baca et al. · 2006 [cited by applicant]
US 7060808B1 · Goldstein et al. · 2006 [cited by applicant]
US 7087409B2 · Barbas et al. · 2006 [cited by applicant]
US 7098002B1 · Rubenstein et al. · 2006 [cited by applicant]
US 7118879B2 · Ladner et al. · 2006 [cited by applicant]
US 7157418B1 · McDonald et al. · 2007 [cited by applicant]
US 7169901B2 · Baca et al. · 2007 [cited by applicant]
US 7208293B2 · Ladner et al. · 2007 [cited by applicant]
US 7226596B2 · Bodary et al. · 2007 [cited by applicant]
US 7297334B2 · Baca et al. · 2007 [cited by applicant]
US 7304143B2 · Goddard et al. · 2007 [cited by applicant]
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7341720B2 · Stefano et al. · 2008 [cited by applicant]
US 7365166B2 · Baca et al. · 2008 [cited by applicant]
US 7375193B2 · Baca et al. · 2008 [cited by applicant]
US 7452535B2 · Davis et al. · 2008 [cited by applicant]
US 7465790B2 · Waldmann et al. · 2008 [cited by applicant]
US 7608591B2 · Liu et al. · 2009 [cited by applicant]
US 7666817B2 · Daugherty et al. · 2010 [cited by applicant]
US 8399219B2 · Stagliano et al. · 2013 [cited by applicant]
US 8513390B2 · Stagliano et al. · 2013 [cited by applicant]
US 8518404B2 · Daugherty et al. · 2013 [cited by applicant]
US 8529898B2 · Daugherty et al. · 2013 [cited by applicant]
US 8541203B2 · Daugherty et al. · 2013 [cited by applicant]
US 8563269B2 · Stagliano et al. · 2013 [cited by applicant]
US 8809504B2 · Lauermann · 2014 [cited by applicant]
US 8993266B2 · Stagliano et al. · 2015 [cited by applicant]
US 9169321B2 · Daugherty et al. · 2015 [cited by applicant]
US 9453078B2 · Stagliano et al. · 2016 [cited by applicant]
US 10059762B2 · Stagliano et al. · 2018 [cited by applicant]
US 10077300B2 · Daugherty et al. · 2018 [cited by applicant]
US 10118961B2 · Stagliano et al. · 2018 [cited by applicant]
US 10875913B2 · Stagliano et al. · 2020 [cited by applicant]
US 20020048578A1 · Frewin et al. · 2002 [cited by applicant]
US 20020168690A1 · Miller et al. · 2002 [cited by applicant]
US 20030021791A1 · Kassis et al. · 2003 [cited by applicant]
US 20030134824A1 · Breslow et al. · 2003 [cited by applicant]
US 20040014652A1 · Trouet et al. · 2004 [cited by applicant]
US 20040053829A1 · Pfizenmaier et al. · 2004 [cited by applicant]
US 20040082039A1 · Gillies et al. · 2004 [cited by applicant]
US 20040146516A1 · Roben et al. · 2004 [cited by applicant]
US 20040147444A1 · Chernajovsky et al. · 2004 [cited by applicant]
US 20040185053A1 · Govindan · 2004 [cited by applicant]
US 20040213797A1 · Bodmer et al. · 2004 [cited by applicant]
US 20040258677A1 · Waldmann et al. · 2004 [cited by applicant]
US 20040259768A1 · Lauermann · 2004 [cited by applicant]
US 20040265274A1 · Wei et al. · 2004 [cited by applicant]
US 20050042680A1 · Fipula et al. · 2005 [cited by applicant]
US 20050106100A1 · Harris et al. · 2005 [cited by applicant]
US 20050136049A1 · Ledbetter et al. · 2005 [cited by applicant]
US 20050196754A1 · Drmanac et al. · 2005 [cited by applicant]
US 20050208558A1 · Venter et al. · 2005 [cited by applicant]
US 20050255042A1 · Lam et al. · 2005 [cited by applicant]
US 20050255555A1 · Johns et al. · 2005 [cited by applicant]
US 20050277160A1 · Shiba et al. · 2005 [cited by applicant]
US 20050287155A1 · Santi et al. · 2005 [cited by applicant]
US 20060018911A1 · Ault-Riche et al. · 2006 [cited by applicant]
US 20060078901A1 · Buchreiser et al. · 2006 [cited by applicant]
US 20060121570A1 · Barbas et al. · 2006 [cited by applicant]
US 20060228348A1 · Stefano · 2006 [cited by applicant]
US 20060024606A1 · Morgan et al. · 2006 [cited by applicant]
US 20060246066A1 · Morgan et al. · 2006 [cited by applicant]
US 20060252130A1 · Boehm et al. · 2006 [cited by applicant]
US 20060265274A1 · Commins et al. · 2006 [cited by applicant]
US 20070041904A1 · Jiang et al. · 2007 [cited by applicant]
US 20070061916A1 · Kovalic et al. · 2007 [cited by applicant]
US 20070065878A1 · Daugherty et al. · 2007 [cited by applicant]
US 20070083334A1 · Mintz et al. · 2007 [cited by applicant]
US 20080107660A1 · Self · 2008 [cited by applicant]
US 20090023602A1 · Fellouse et al. · 2009 [cited by applicant]
US 20090123467A1 · Bedi et al. · 2009 [cited by applicant]
US 20090304719A1 · Daugherty et al. · 2009 [cited by applicant]
US 20100168019A1 · Gengrinovitch · 2010 [cited by applicant]
US 20100189651A1 · Stagliano et al. · 2010 [cited by applicant]
US 20100189727A1 · Rodeck et al. · 2010 [cited by applicant]
US 20100221212A1 · Stagliano et al. · 2010 [cited by applicant]
US 20110178279A1 · Williams et al. · 2011 [cited by applicant]
US 20120149061A1 · Stagliano et al. · 2012 [cited by applicant]
US 20120207756A1 · Stagliano et al. · 2012 [cited by applicant]
US 20120237512A1 · Daugherty et al. · 2012 [cited by applicant]
US 20120237977A1 · Daugherty et al. · 2012 [cited by applicant]
US 20120244154A1 · Daugherty et al. · 2012 [cited by applicant]
US 20130060010A1 · Williams et al. · 2013 [cited by applicant]
US 20140024810A1 · Stagliano et al. · 2014 [cited by applicant]
US 20140045195A1 · Daugherty et al. · 2014 [cited by applicant]
US 20150203559A1 · Stagliano et al. · 2015 [cited by applicant]
US 20160122425A1 · Daugherty et al. · 2016 [cited by applicant]
EP 0329185 · 1989 [cited by applicant]
EP 0444158 · 1990 [cited by applicant]
EP 0623679 · 2003 [cited by applicant]
EP 1550729 · 2003 [cited by applicant]
EP 1579873 · 2005 [cited by applicant]
EP 1770099 · 2007 [cited by applicant]
WO WO1995011703 · 1995 [cited by applicant]
WO WO1996005863 · 1996 [cited by applicant]
WO WO1996034892 · 1996 [cited by applicant]
WO WO1997018236 · 1997 [cited by applicant]
WO WO1997031024 · 1997 [cited by applicant]
WO 1998011126 · 1998 [cited by applicant]
WO WO2000004192 · 2000 [cited by applicant]
WO WO2000018962 · 2000 [cited by applicant]
WO WO2000023472 · 2000 [cited by applicant]
WO WO2000034519 · 2000 [cited by applicant]
WO WO2000064946 · 2000 [cited by applicant]
WO WO2001091798 · 2001 [cited by applicant]
WO WO2002030460 · 2002 [cited by applicant]
WO WO2002060488 · 2002 [cited by applicant]
WO WO2002066058 · 2002 [cited by applicant]
WO WO2002066656 · 2002 [cited by applicant]
WO WO2003012105 · 2003 [cited by applicant]
WO WO2003020212 · 2003 [cited by applicant]
WO WO2003068934 · 2003 [cited by applicant]
WO WO2004009638 · 2004 [cited by applicant]
WO WO2004027045 · 2004 [cited by applicant]
WO 2004111192 · 2004 [cited by applicant]
WO WO2005007198 · 2005 [cited by applicant]
WO WO2005042034 · 2005 [cited by applicant]
WO WO2005051315 · 2005 [cited by applicant]
WO WO2005083431 · 2005 [cited by applicant]
WO WO2006090813 · 2006 [cited by applicant]
WO WO2007014744 · 2007 [cited by applicant]
WO WO2007026972 · 2007 [cited by applicant]
WO 2007064759 · 2007 [cited by applicant]
WO WO2007066106 · 2007 [cited by applicant]
WO WO2007099348 · 2007 [cited by applicant]
WO WO2007105027 · 2007 [cited by applicant]
WO WO2007106415 · 2007 [cited by applicant]
WO WO2007109254 · 2007 [cited by applicant]
WO 2008052322 · 2008 [cited by applicant]
WO 2008068637 · 2008 [cited by applicant]
WO WO2009002846 · 2008 [cited by applicant]
WO WO2009018500 · 2009 [cited by applicant]
WO WO2009025846 · 2009 [cited by applicant]
WO WO2009026274 · 2009 [cited by applicant]
WO WO2009039409 · 2009 [cited by applicant]
WO WO2010077643 · 2010 [cited by applicant]
WO WO2010081173 · 2010 [cited by applicant]
Benjamin et al., “Tolerance to rat monoclonal antibodies: Implications for serotherapy”, J. Exp. Med. (1986) 163(6):1539-1552. [cited by applicant]
Brinks et al., “Preclinical models Used for Immunogenicity Prediction of Therapeutic Proteins”, Pharm. Res. (2013) 30:1719-1728. [cited by applicant]
Chiller et al. “Cellular events during induction of immunologic unresponsiveness in adult mice”, J. Immunol. (1971) 106(6):1647-1653. [cited by applicant]
Chirinos-Rojas et al, “Use of a solid-phase random peptide library to identify inhibitors of TNF-alpha mediated cytotoxicity in vitro”, Cytokine (1997) 9(4):226-232. [cited by applicant]
Cwirla et al, “Peptides on phage: a vast library of peptides for identifying ligands”, Proc. Natl. Acad. Sci. USA (1990) 87(16):6378-6382. [cited by applicant]
Geysen et al., “A Priori Delineation of a Peptide Which Mimics a Discontinuous Antigenic Determinant”, Mol. Immunol. (1986) 23(7):709-715. [cited by applicant]
Geysen et al., “Strategies for epitope analysis using peptide synthesis”, J. Immunol. Meth. (1987) 102(2):259-274. [cited by applicant]
Golay et al., “Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays”, Arch Biochem Biophys. (2012) 526(2):146-153. [cited by applicant]
Gravanis et al., “The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessme… [cited by applicant]
Hay et al., “Clinical development success rates for investigational drugs”, Nat. Biotech. (2014) 32(1):40-51. [cited by applicant]
Leitner et al., “A mimotope defined by phage display inhibits IgE binding to the plant panallergen profilin”, Eur. J. Immunol. (1998) 28(9):2921-2927. [cited by applicant]
Lichtenstein, Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment Therap. Adv. Gastroenterol. Jul. 2013:6(4):269-932. [cited by applicant]
Lopez-Olin et al., “Protease degradomics: a new challenge for proteomics”, Nat. Rev. Mol. Cell Bio. (2002) 3:509-519. [cited by applicant]
Mitchison, NA, “The dosage requirements for immunological paralysis by soluble proteins”, Immunol. (1968) 15(4):509-530. [cited by applicant]
Moore et al., “Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans”, J. Viral. (1993) 67(2)… [cited by applicant]
Morris GE, “Epitope Mapping: B-cell Epitopes”, Encyclopedia of Life Sciences (2007) p. 1-3. [cited by applicant]
NEB website http://www.neb.com/neb/products/phd/phd. html “Phage Display Library Kits”, “Wayback Machine (Archive)” pp. 1-5, downloaded Jan. 11, 2012. [cited by applicant]
Roitt et al., “Immunochemical Techniques”, Roitt's Essential Immunology (10TH edition), Chapter 6, (2001) pp. 118-120. [cited by applicant]
Sethu et al., “Immunogenicity to Biologics: Mechanisms, Predicition and Reduction”, Arch. Immunol. Ther. Exp. (Warsz) (2012) 60:331-344. [cited by applicant]
Smith & Petrenko, “Phage Display”, Chem. Rev. (1997) 97:391-410. [cited by applicant]
Albright, et al (2005) “Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity”, Mol Cancer Ther. 4(5), pp. 7517-7560. [cited by applicant]
Van Valckenborgh, et al (2005) “Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model”, Leukemia 19(9), pp. 1628-1633. [cited by applicant]
Maeda et al., “Engineering of functional chimeric protein GVargula Luciferase”, Anal. Biochem. (1997) 249(2):147-152. [cited by applicant]
Colman P.M., “Effects of amino acid sequence changes on antibody antigen interactions”, Res. Immunol. (1994) 145(1):33-36. [cited by applicant]
Anderson, et al. Selective Photothermolysis: Precise Microsurgery by Selective Absorption of Pulsed Radiation. Science. Apr. 29, 1983; 220(4596):524-7. [cited by applicant]
Armentano, et al. Induction of Covalent Binding Antibodies. Immunol Lett. Feb. 28, 2006; 103(1):51-7. [cited by applicant]
Baron, et al. From Cloning to a Commercial Realization: Human Alpha Interferon. Critical Review in Biotechnology. 1990; 10(3):179-190. [cited by applicant]
Bartenschlager, et al. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol. 1995. 69(1):198-205. [cited by applicant]
Bessette, et al. Construction of designed protein libraries using gene assembly mutagenesis. Methods Mol Biol. 2003; 231:29-37. [cited by applicant]
Bessette, et al. Rapid Isolation of High-Affinity Protein Binding Peptides Using Bacterial Display. Protein Engineering, Design & Selection 2004, 17(10):731-739. [cited by applicant]
Boder, et al. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A. Sep. 26, 2000; 97(20):10701-5. [cited by applicant]
Boder, et al. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. Jun. 1997; 15(6):553-7. [cited by applicant]
Bupp, et al. Altering retroviral tropism using a random-display envelope library. Mol Ther. Mar. 2002; 5(3):329-35. [cited by applicant]
Caliceti, et al. Preparation and properties of monomethoxy poly(ethylene glycol) doxorubicin conjugates linked by an amino acid or a peptide as spacer. Farmaco Jul. 1993; 48(7):919-32. [cited by applicant]
Caron, et al. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer. Feb. 1, 1994; 73(3 Suppl):1049-56. [cited by applicant]
Chang, et al. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model. BMC Cancer. May 23, 2007; 87(7):1-6. [cited by applicant]
Chari, et al. C242-DM1: A tumor-activated prodrug that shows exceptional activity in human colon tumor xenograft models at non-toxic doses. Proceedings of the American Association for Cancer Research Annual Meeting, Mar… [cited by applicant]
Chari, et al. Integration of SB-40875 into combination treatments of human colon xenograft models of SCID mice. Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 2000, 41:291 (91 [cited by applicant]
Chari. Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs. Accounts of Chemical Research. Jan. 2008; 41(1):98-107. [cited by applicant]
Chari. Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy. Advanced Drug Delivery Reviews Apr. 6, 1998; 31(1-2):89-104. [cited by applicant]
Chen, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen. J Mol Biol. Nov. 5, 1999; 293(4):865-881. [cited by applicant]
Chmura, et al. Antibodies with infinite affinity. Proc Natl Acad Sci U S A. Jul. 17, 2001; 98(15):8480-4. [cited by applicant]
Cho, et al. N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease. J Biol Chem. 2001. 276(48):44581-9. [cited by applicant]
Co, et al. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol. Feb. 15, 1992; 148(4):1149-54. [cited by applicant]
Cooper, et al. Galactose oxidase from Polyporus circinatus, Fr. J Biol Chem. Mar. 1959; 234(3):445-8. [cited by applicant]
Daugherty, et al. Flow cytometric screening of cell-based libraries. J Immunol Methods. Sep. 21, 2000; 243(1-2):211-27. [cited by applicant]
Daugherty, et al. Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc Natl Acad Sci U S A. Feb. 29, 2000; 97(5):2029-34. [cited by applicant]
Donaldson, et al. Design and development of masked therapeutic antibodies to limit off-target effects—Application to anti-EGFR antibodies. Cancer Biology & Therapy. Nov. 2009; 8(22):1-6. [cited by applicant]
Dufner et al. (2006) “Harnessing Phage and Ribosome Display for Antibody Optimisation” [cited by applicant]
European Search Report for European Application No. EP 08795508.4, dated Feb. 17, 2011. [cited by applicant]
Facchiano, et al. Identification of a Novel Domain of Fibroblast Growth Factor 2 Controlling Its Angiogenic Properties. The Journal of Biological Chemistry 2003, 278(10):8751-8760. [cited by applicant]
Ford, et al. Fusion tails for the recovery and purification of recombinant proteins. Protein expression and purification 1991, 2:95-107. [cited by applicant]
Fricker. MMP-8: a new target for atherosclerosis? Drug Discov Today. Jan. 15, 2002; 7(2):86-88. [cited by applicant]
Funahashi, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008. 68(12):4727-35. [cited by applicant]
Georgiou, et al. Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat Biotechnol. Jan. 1997; 15(1):29-34. [cited by applicant]
Georgiou. Analysis of large libraries of protein mutants using flow cytometry. Adv Protein Chem. 2000; 55:293-315. [cited by applicant]
Gerspach, et al. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death and Differentiation. 2006; 13:273-284. [cited by applicant]
Gilliland, et al. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens. Jan. 1996; 47(1):1-20. [cited by applicant]
Gilliland, et al. Elimination of the Immunogenicity of Therapeutic Antibodies. Journal of Immunology. 1999; 162:3663-3671. [cited by applicant]
Grussenmeyer, et al. Complexes of polyoma virus medium T antigen and cellular proteins. Proc Natl Acad Sci U S A. Dec. 1985; 82(23):7952-4. [cited by applicant]
Guay, et al. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides. Eur J Biochem. 2000. 267(20):6311-8. [cited by applicant]
Hagedorn, et al. A Short Peptide Domain of Platelet Factor 4 Blocks Angiogenic Key Events Induced by FGF-2. The FASEB Journal 2001. 15(3):550-552. [cited by applicant]
Hale. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology. Dec. 1995; 1(3):175-187. [cited by applicant]
Harris, et al. Generation of Anti-complement “Prodrugs”. The Journal of Biological Chemistry. Sep. 2003; 278(38):36068-36076. [cited by applicant]
Hillmen, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. Sep. 21, 2006; 355(12):1233-43. [cited by applicant]
Holliger et al. (1993) “‘Diabodies’: Small Bivalent and Bispecific Antibody Fragments” Proc. Natl. Acad. Sci. USA 90(14):6444-6449. [cited by applicant]
Hopp, et al. A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification. Nature Biotechnology 1988 6:1204-1210. [cited by applicant]
Horton, et al. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. Apr. 15, 1989; 77(1):61-8. [cited by applicant]
Iiyama, et al. Patterns of Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 Expression in Rabbit and Mouse Atherosclerotic Lesions and at Sites Predisposed to Lesion Formation. Circulation Researc… [cited by applicant]
Immordino, et al. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. Sep. 2006; 1(3):297-315. [cited by applicant]
International Search Report for International Application No. PCT/US2008/009974, dated Mar. 23, 2009. [cited by applicant]
International Search Report for International Application No. PCT/US2006/034096, dated Nov. 13, 2007. [cited by applicant]
Isaacs, et al. Helplessness as a Strategy for Avoiding Antiglobulin responses to Therapeutic Monoclonal Antibodies. Therapeutic Immunology. Dec. 1994; 1(6):303-312. [cited by applicant]
Jambunathan, Kalyani et al; “Design of a Serum Stability Tag for Bioactive Peptides”; Protein & Peptide Letters, 21; (2014); pp. 32-38. [cited by applicant]
Jensen-Jarolim, et al. Peptide mimotopes displayed by phage inhibit antibody binding to bet v 1, the major birch pollen allergen, and induce specific IgG response in mice. FASEB J. Dec. 1998; 12(15):1635-42. [cited by applicant]
Johnson, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. Nov. 1997; 176(5):1215-24. [cited by applicant]
Kam, et al. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res. 1998. 58(23):5577-81. [cited by applicant]
Karush, et al. Interaction of a bivalent ligand with IgM anti-lactose antibody. Biochemistry. May 29, 1979; 18(11):2226-32. [cited by applicant]
Kline et al. (2004) “Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9” [cited by applicant]
Knight, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. Nov. 1993; 30(16):1443-53. [cited by applicant]
La Rocca, et al. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. Apr. 5, 2004; 90(7):1414-21. [cited by applicant]
Lambert, et al. Pharmacokinetics, in vivo stability, and toxicity of the tumor-activated prodrug. Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 1998, 39:522 (89th annual meeting of the… [cited by applicant]
Lamoyi, et al. Preparation of F(ab′)2 fragments from mouse IgG of various subclasses. J Immunol Methods. Jan. 28, 1983; 56(2):235-43. [cited by applicant]
Leger, et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies. 1997; 8(1):3-16. [cited by applicant]
Li et al. (2007) “Self-Masking in an Intact ERM-Merlin Protein: An Active Role for the Central Alpha-Helical Domain” [cited by applicant]
Liu, et al. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. Jun. 1, 2003; 63(11):2957-64. [cited by applicant]
Lowman, et al. Selecting high-affinity binding proteins by monovalent phage display. Biochemistry. Nov. 12, 1991; 30(45):10832-8. [cited by applicant]
Lozano, et al. Solution Structure and Interaction with Basic and Acidic Fibroblast Growth Factor of a 3-kDa Human Platelet Factor-4 Fragment with Antiangiogenic Activity. The Journal of Biological Chemistry 2001. 276(38… [cited by applicant]
Mathieu, et al. Substrate specificity of schistosome versus human legumain determined by P1-P3 peptide libraries. Mol Biochem Parasitol. Apr. 30, 2002; 121(1):99-105. [cited by applicant]
Mattheakis, et al. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci U S A. Sep. 13, 1994; 91(19):9022-6. [cited by applicant]
Melton et al. (1999) “The Use of Prodrugs in Targeted Anticancer Therapies” [cited by applicant]
Mhaka et al; “A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer”; Bioorg Med Chem Lett. (2002): 12(17):2459-61. [cited by applicant]
Mitra, et al. Reagents for the cross-linking of proteins by equilibrium transfer alkylation. J. Am. Chem. Soc., 1979; 101(11):3097-3110. [cited by applicant]
Müller, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol. Sep. 2003; 21(9):1040-6. Epub Aug. 3, 2003. [cited by applicant]
Nagahira, et al. Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor-α (TNF-α). J Immunol Methods. Jan. 1, 1999; 222(1-2):83-92. [cited by applicant]
Ngo et al. (1994) “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox” [cited by applicant]
Nicaise, et al. Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold. Protein Sci. 2004. 13(7):1882-91. [cited by applicant]
Nichifor, et al. Macromolecular Prodrugs of 5-fluorouracil. 2: Enzymatic Degradation. Journal Controlled Release 1996 39(1):79-92. [cited by applicant]
Nicolaisen-Strouss, et al. Natural feline leukemia virus variant escapes neutralization by a monoclonal antibody via an amino acid change outside the antibody-binding epitope. Journal of Virology. 1987. 61(11):3410-3415. [cited by applicant]
Nilsson, et al. Expression and purification of recombinant insulin-like growth factors from [cited by applicant]
Nilsson, et al. Immobilization and purification of enzymes with staphylococcal protein A gene fusion vectors. EMBO J. Apr. 1985; 4(4):1075-80. [cited by applicant]
Olsen, et al. High-throughput FACS method for directed evolution of substrate specificity. Methods Mol Biol. 2003; 230:329-42. [cited by applicant]
Palandoken et al. (2005) “Amiloride peptide conjugates: prodrugs for sodium-proton exchange inhibition” [cited by applicant]
Parham. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol. Dec. 1983; 131(6):2895-902. [cited by applicant]
Presta, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. Oct. 15, 1997; 57(20):4593-9. [cited by applicant]
Putnam, et al. Complete amino acid sequence of the Mu heavy chain of a human IgM immunoglobulin. Science. Oct. 19, 1973; 182(109):287-91. [cited by applicant]
Rader, et al. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci U S A. Apr. 29, 2003; 100(9):5396-400. [cited by applicant]
Ribas, et al. Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte-Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer. Oncologist, Jul. 2007; 12:873-883. [cited by applicant]
Rice, et al. Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands. Protein Sci. Apr. 2006; 15(4):825-36. [cited by applicant]
Rodwell, et al. Linker Technology: Antibody-Mediated Delivery Systems. Biotechnology. 1985. 3:889-894. [cited by applicant]
Samel et al. (2003) “Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation” [cited by applicant]
Scheraga. Predicting three-dimensional structures of oligopeptides, In: Reviews in Computational Chemistry. vol. III, Lipkowitz and Boyd, eds., New York; 1992:73-142. [cited by applicant]
Scott, et al. Searching for peptide ligands with an epitope library. Science. Jul. 27, 1990; 249(4967):386-90. [cited by applicant]
Segerström et al. (2006) “The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts” [cited by applicant]
Self, et al. How specific are therapeutic monoclonal antibodies? www.thelancet.com. Apr. 2006; 367(960):1038-1039. [cited by applicant]
Self, et al. Light activatable antibodies: Models for remotely activatable proteins. Nature Medicine. Jul. 1996; 2(7):817-820. [cited by applicant]
Self, et al. Light-Directed Activation of Human T-Cells. ChemMedChem. 2007; 2:1587-1590. [cited by applicant]
Shusta, et al. Biosynthetic polypeptide libraries. Curr Opin Biotechnol. Apr. 1999; 10(2):117-22. [cited by applicant]
Sidhu, et al. Exploring protein-protein interactions with phage display. Chembiochem. 2003. 4(1):14-25. [cited by applicant]
Skolnick et al. (2000) “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era” [cited by applicant]
Smith, et al. Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin αIIb β3. J Biol Chem. 1995. 270(51):30486-90. [cited by applicant]
Smith, et al. Single-step purification of polypeptides expressed in [cited by applicant]
Stanworth, et al. Handbook of experimental immunology, vol. 1, 2nd ed., Weir ed., chapter 10, Blackwell Scientific Publications, London; 1973. [cited by applicant]
Stryer et al. (1988) “Levels of Structure in Protein Architecture” [cited by applicant]
Takagi, et al. A new approach for alteration of protease functions: pro-sequence engineering. Appl Microbiol Biotechnol. 2003. 63(1):1-9. [cited by applicant]
Thomas et al. “Engineering Enzymatically Activated Targeting Ligands Using Bacterial Peptide Display Libraries” Div of Biochem Tech, The 236 [cited by applicant]
Thompson, et al. The modulation of Protein A-IgG(Fc) binding by the reversible addition of 2-nitrobenzyl groups. Biochemical Society Transactions. May 1995; vol. 23(2): 155S. [cited by applicant]
Thompson, et al. A Simple Procedure for the Photoregulation of Chymotrypsin Activity. Photochemical & Photobiological Sciences. 2006; 5:326-330. [cited by applicant]
Thompson, et al. Light Activation of Anti-CD3 in vivo Reduces the Growth of an Aggressive Ovarian Carcinoma. ChemMedChem. 2007; 2:1591-1593. [cited by applicant]
Thompson, et al. Photocleavable Nitrobenzyl-Protein Conjugates. Biochemical and Biophysical Research Communications. Jun. 1994; 201(3):1213-1219. [cited by applicant]
Thompson, et al. The construction and in vitro testing of photo-activatable cancer targeting folated anti-CD3 conjugates. Biochemical and Biophysical Research Communication. 2008; 366:526-531. [cited by applicant]
Thompson, et al. The Construction of a Functional Photoactivatable Cancer Targeting Bispecific Antibody Conjugate. ChemMedChem. 2007; 2:1162-1164. [cited by applicant]
Trouet, et al. CPI-0004Na: An extracellular tumor-activated prodrug of doxorubicin. Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 2000, 41:522 (91 [cited by applicant]
Trouet, et al. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. Cancer Research Apr. 2001 61(7):2843-6. [cited by applicant]
Tuve, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. Jun. 15, 2007; 67(12):5929-39. [cited by applicant]
United Kingdom Search Report Great Britain Application No. GB0902572.7, dated Jun. 19, 2009. [cited by applicant]
Vartak, et al. Matrix metalloproteases: Underutilized targets for drug delivery. Journal of Drug Targeting. Jan. 2007; 15(1):1-20. [cited by applicant]
Watermann, I. et al: “Activation of CD95L fusion protein prodrugs by tumor-associated proteases”; Cell Death Differ. 14(4): (2007); pp. 765-774. [cited by applicant]
Weisel, et al. (2001) The Structure and Function of the αC Domains of Fibrinogen. Annals New York Academy of Sciences. 312-327. [cited by applicant]
Werther, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. Dec. 1, 1996; 157(11):4986-9… [cited by applicant]
Wiebe, et al. Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection. Advanced Drug Delivery Reviews Oct. 18, 1999; 39(1-3):63-80. [cited by applicant]
Wilson, et al. The use of mRNA display to select high-affinity protein-binding peptides. Proc Natl Acad Sci U S A. Mar. 27, 2001; 98(7):3750-5. Epub Mar. 13, 2001. [cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2010/025121, dated Nov. 5, 2010. [cited by applicant]
Wu et al. (1999) “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues” [cited by applicant]
Wuest et al. (2002) “TNF-Selectokine: A Novel Prodrug Generated for Tumor Targeting and Site-Specific Activation of Tumor Necrosis Factor” [cited by applicant]
Xie, et al. Identification of the Fibroblast Growth Factor (FGF)-interacting Domain in a Secreted FGF-binding Protein by Phage Display. The Journal of Biological Chemistry 2006. 281(2):1137-1144. [cited by applicant]
Yang, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. Nov.-Dec. 2007; 30(8):825-30. [cited by applicant]
Yu et al. (2008) “Interaction between Bevacizumab and Murine VEGF-A: A Reassessment” [cited by applicant]
Zhou, et al. Specific Antibodies to the External Vestibule of Voltage-gated Potassium Channels Block Current. J. Gen. Physiol. 1998. 111:555-563. [cited by applicant]
Zhu & Witte (1999) “Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor” [cited by applicant]